BridgeMD
A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma
EU CTIS ID: 2023-505672-30-00
What this study is testing
To evaluate the clinical activity of RO7247669 at 600 mg and 1200 mg every 3 weeks (Q3W) on the basis of progression-free survival (PFS)
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- 1. Histologically confirmed unresectable or metastatic melanoma, per the American Joint Committee on Cancer (AJCC) staging system (unresectable Stage III or Stage IV)
- 2. Radiologically measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
- 3. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
- 4. Known v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) V600 mutation status
- 5. Adequate cardiovascular, hematological, hepatic and renal function.
- 6. Participants must have known PD-L1 status
You likely can't join if
- 1. Pregnancy, lactation, or breastfeeding
- 2. Participants must not have ocular melanoma
- 3. Symptomatic central nervous system (CNS) metastases.
- 4. Significant cardiovascular/cerebrovascular disease within 6 months prior to randomization
- 5. Active or history of autoimmune disease or immune deficiency with some exceptions
- 6. Prior systemic anticancer therapy for unresectable or metastatic melanoma
The study team makes the final eligibility decision.
Where it's taking place
- Australia
- Canada
- Brazil
- New Zealand
- Turkey
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Australia; Canada; Brazil; New Zealand; Turkey. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.